Barnes E A, Thomas G, Ackerman I, Barbera L, Letourneau D, Lam K, Makhani N, Sankreacha R
Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada.
Int J Gynecol Cancer. 2007 Jul-Aug;17(4):821-6. doi: 10.1111/j.1525-1438.2007.00888.x. Epub 2007 Mar 13.
Brachytherapy (BT) is an essential component of radical treatment for cervix cancer. Uterine perforation is a potential complication of intrauterine applicator (tandem) insertion. Postprocedure pelvic computed tomography (CT) scans are routinely performed at this center. The objective of this study was to prospectively compare radiation oncologists' (RO) clinical impression of satisfactory tandem placement with actual tandem placement as determined from pelvic CT. Patients with cervix cancer undergoing low-dose rate BT from April 2003 to December 2005 were prospectively identified. After tandem placement, patients were brought to the radiotherapy department for pelvic imaging (plain films and CT). Prior to viewing imaging, the RO specified whether they were concerned vs not concerned about uterine perforation. The CT was then reviewed to determine actual tandem placement (perforation vs no perforation). One hundred twenty-four sequential tandem insertions were performed in 114 patients and eligible for analysis. The incidence of CT detected uterine perforation was 13.7% (17/124). Physician concern, age greater than or equal to 60, and tumor size were significant predictors of uterine perforation (P < 0.0001, P= 0.0019, and P= 0.0016, respectively). The overall sensitivity and specificity for physician concern was 52.9% and 84.1%, respectively. CT detected perforation in 8.2% (8/98) of insertions where the RO was clinically confident of correct tandem placement. Pelvic CT was a useful modality to accompany clinical assessment in identifying uterine perforation in cervix BT. As a low but potentially clinical significant number of perforations identified on CT were not suspected clinically, we recommend acquiring pelvic imaging in all patients following tandem insertion to ensure intrauterine tandem positioning.
近距离放射治疗(BT)是宫颈癌根治性治疗的重要组成部分。子宫穿孔是宫腔施源器(串联器)插入的一种潜在并发症。该中心常规在术后进行盆腔计算机断层扫描(CT)。本研究的目的是前瞻性比较放射肿瘤学家(RO)对串联器放置满意的临床印象与通过盆腔CT确定的实际串联器放置情况。前瞻性确定了2003年4月至2005年12月期间接受低剂量率BT治疗的宫颈癌患者。串联器放置后,患者被送至放疗科进行盆腔成像(平片和CT)。在查看影像之前,RO指明他们是否担心子宫穿孔。然后对CT进行复查以确定实际串联器放置情况(穿孔与否)。对114例患者进行了124次连续串联器插入并符合分析条件。CT检测到的子宫穿孔发生率为13.7%(17/124)。医生的担心、年龄大于或等于60岁以及肿瘤大小是子宫穿孔的显著预测因素(分别为P < 0.0001、P = 0.0019和P = 0.0016)。医生担心的总体敏感性和特异性分别为52.9%和84.1%。在RO临床确信串联器放置正确的插入操作中,CT检测到8.2%(8/98)存在穿孔。盆腔CT是在宫颈癌BT中辅助临床评估以识别子宫穿孔的有用手段。由于CT上发现的穿孔数量虽少但可能具有临床意义,而临床上未怀疑,我们建议在所有患者串联器插入后进行盆腔成像以确保宫腔串联器的定位。